Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (82007)	3/16/2001 12:57:12 PM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

UNVC GlaxoSmithKline are all over the world, trades on London and NYSE....this could be very big

To: Joe Copia who wrote (82007)	3/16/2001 1:03:50 PM
From: Joe Copia	Respond to of 150070

Friday March 16, 11:57 am Eastern Time Press Release Major Initiative by GlaxoSmithKline Biologicals Will Save Even More Lives with UNIVEC Auto-Disable Syringe Which Prevents Re-Use FARMINGDALE, N.Y.--(BUSINESS WIRE)--March 16, 2001--The Farmingdale-based UNIVEC, Inc. (OTCBB:UNVC - news), today applauded GlaxoSmithKline Biologicals for a major contribution to international public health. Starting in March 2001, GlaxoSmithKline (GSK) Biologicals will use the Univec Auto-Disable Syringes with all vials of liquid pediatric vaccines delivered to developing countries and emerging markets. GlaxoSmithKline Biologicals is the first vaccine manufacturer to take this initiative, which will save lives and prevent illness by further helping to stem the spread of infections such as hepatitis B or HIV (the AIDS virus) through the re-use of contaminated syringes. The auto-disable syringes, developed and manufactured by UNIVEC will be delivered to developing countries by GSK with all vials of its liquid pediatric vaccines. The Univec design ensures that when the plunger is fully depressed it locks in that position and cannot be pulled back for further use. While standard disposable syringes and needles are now used in nearly half of all immunizations, the practice of re-using them is widespread particularly in developing countries, with the consequent risk of transmitting blood-borne diseases from vaccine to vaccine. It is now WHO-UNICEF policy that the A-D syringe is the equipment of choice for administering vaccines, both in routine immunization and in mass vaccination campaigns. Jean Stephenne, President and General Manager GSK Biologicals, said: ``At GlaxoSmithKline, as well as supplying safe and effective vaccines, we care about what happens to our products after they leave the company. As part of that continuing concern, we have now become the first vaccine manufacturer to supply auto-disable syringes with all vials of our liquid pediatric vaccines delivered to developing countries. We believe this is a further important contribution to worldwide public health.'' GSK Biologicals will start supplying all vials of liquid pediatric vaccines with A-D syringes to countries including Africa, the Caribbean, Latin America, Eastern Europe, Middle East, South East and South West Asia and other emerging markets. Located at Rixensart in Belgium, GSK Biologicals specialize in vaccine research, development and production. It is part of GlaxoSmithKline, one of the world's leading pharmaceutical and healthcare companies. GSK Biologicals employs more than 900 research scientists in its quest for new vaccines. They are involved in developing and clinically testing more cost-effective and convenient products to prevent the infections, which cause serious worldwide medical problems. In 2000, the company distributed over 1.1 billion doses of vaccines to 177 countries, an average of 35 doses a second. GlaxoSmithKline (NYSE: GSK - news) -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. UNIVEC is a world leader in auto-disable syringes and is leading the global movement for a conversion to auto-disable syringes from traditional multi-use syringes. Traditional multi-use disposable syringes are acknowledged by the World Health Organization to be responsible for the spread of disease to millions of people each year. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company's Securities and Exchange filings under ``Risk Factors,'' including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company's proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks.) Contact: UNIVEC, Inc. Joel Schoenfeld, 631/777-2000 UNIVEC@UNIVEC.com

To: Joe Copia who wrote (82007)	3/16/2001 1:05:15 PM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

GLAXOSMITHKLINE PLC: GREY GLOBAL GROUP INC - Selects MediaCom as Media Buying Agency of Record New York, New York, Mar 16, 2001 (Market News Publishing via COMTEX) -- GlaxoSmithKline announced that it has chosen MediaCom, a division of Grey Global Group, as its consumer media buying agency of record. The selection follows a decision by GlaxoSmithKline, one of the world's leading research-based pharmaceutical and consumer healthcare companies, to consolidate all its consumer advertising media buying with one agency in an effort to leverage the newly combined company's buying power, to streamline decision-making and to achieve the greatest possible efficiency, effectiveness, and return on its advertising. MediaCom was selected after an evaluation process in which GlaxoSmithKline's four incumbent agencies were asked to submit proposals. The assignment was based on a variety of criteria, including efficiencies, strategic thinking and a creative approach to media. GlaxoSmithKline will continue to work with a variety of existing agencies to develop advertising strategies, creative approaches, and media planning. MediaCom is one of the world's largest media services companies. With over $10 billion in billings and offices in 67 countries, MediaCom provides business building media solutions for the world's largest advertisers. GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. CONTACT: TEL: (919) 483 2839 GlaxoSmithKline, Mary Anne Rhyne TEL: (212) 546-2422 MediaCom, Jan Snead MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041. (C) 2001 Market News Publishing Inc. -0- KEYWORD: New York, New York * end of story *